ABIONYX Pharma SA (id:10940 ABNX)
1.25 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/28/2024 3:51:21 AM)
Exchange closed, opens in 5 hours 8 minutes
About ABIONYX Pharma SA
Market Capitalization 43.87M
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.
| Headquarters (address) |
33 43 av. Georges Pompidou Bât. D2 Balma 31130 France |
| Phone | 33 5 62 24 97 06 |
| Website | https://abionyx.com |
| Employees | 61 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ABNX |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 0.910 - 1.50 |
| Market Capitalization | 43.87M |
| P/E trailing | -10.38 |
| P/E forward | -6.03 |
| Price/Sale | 9.03 |
| Price/Book | 4.35 |
| Beta | 0.053 |
| EPS | -0.100 |
| EPS France (ID:70, base:331) | 3.06 |